請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31491
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許輝吉 | |
dc.contributor.author | Han-Hsiang Huang | en |
dc.contributor.author | 黃涵湘 | zh_TW |
dc.date.accessioned | 2021-06-13T03:13:44Z | - |
dc.date.available | 2006-09-18 | |
dc.date.copyright | 2006-09-18 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-08-10 | |
dc.identifier.citation | Alessi D. R., Cuenda A., Cohen P., Dudley D. T., and Saltiel A. R. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-94.
Avraham H., Park S. Y., Schinkmann K., and Avraham S. (2000). RAFTK/Pyk2-mediated cellular signalling. Cell Signal 12: 123-33. Barbee S. D., and Alberola-Ila J. (2006). Phosphatidylinositol 3-kinase improves the efficiency of positive selection. Int Immunol 18: 921-30. Bashaw G. J., Kidd T., Murray D., Pawson T., and Goodman C. S. (2000). Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor. Cell 101: 703-15. Bennett MR, Evan GI, Schwartz SM. 1995. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circulation Research 77:266-273. Berar V, Blum H, Buendia MA, Craig JR, Dragani TA, Gao YT, Grisham JW, Hall AJ, Kaldor J, Kew MC, Kirby GM, London WT, Marion PL, Miller AB, Monjardino J, Muller N, Nishioka K, Ozturk M, Trichopoulos D. 1994. IARC monographs on the evaluation of carcinogenic risks to humans. In: Hepatitis viruses. Lyon, France: International Agency for Research on Cancer 59. Bosch FX, Munoz N. 1991. Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Houston, Texas: Gulf Publishing Company:35-54. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431. Brose K., Bland K. S., Wang K. H., Arnott D., Henzel W., Goodman C. S., Tessier-Lavigne M., and Kidd T. (1999). Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 96: 795-806. Cardone M. H., Salvesen G. S., Widmann C., Johnson G., and Frisch S. M. (1997). The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 90: 315-23. Carmeliet P., and Tessier-Lavigne M. (2005). Common mechanisms of nerve and blood vessel wiring. Nature 436: 193-200. Caselmann WH. 1996. Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Advances in Virus Research 47:253-302. Challa A. K., Beattie C. E., and Seeger M. A. (2001). Identification and characterization of roundabout orthologs in zebrafish. Mech Dev 101: 249-53. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, Farinati F, Naccarato R. 1999. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85:2132-2137. Clement M. J., Jourdain I., Lachkar S., Savarin P., Gigant B., Knossow M., Toma F., Sobel A., and Curmi P. A. (2005). N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly. Biochemistry 44: 14616-25. Colombo M. 1992. Hepatocellular carcinoma. Journal of Hepatology 15:225-236. Cook JR, Chen JK. 1988. Enhancement of transformed cell groeth in agar by serine protease inhibitors. Journal of Cellular Physiology 136:188-193. Cooper MJ, Mackie CR, Skinner DB, Moosa AR. 1979. A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. British Journal of Surgy 66:120-123. Craig JR. 1997. Chirrhosis, hepatocellular carcinoma, and survival. Hepatology 26:798-799. Craig JR, Peters RL, Edmondson HA. 1989. Tumors of the liver and intraphepatic bile ducts. Fascicle 26, 2nd series.Washington DC: Armed Forces Institue of Pathology. Dallol A., Forgacs E., Martinez A., Sekido Y., Walker R., Kishida T., Rabbitts P., Maher E. R., Minna J. D., and Latif F. (2002). Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 21: 3020-8. Derijard B., Hibi M., Wu I. H., Barrett T., Su B., Deng T., Karin M., and Davis R. J. (1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-37. Dickson B. J. (2001). Rho GTPases in growth cone guidance. Curr Opin Neurobiol 11: 103-10. Dudley D. T., Pang L., Decker S. J., Bridges A. J., and Saltiel A. R. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92: 7686-9. Eilers M., Schirm S., and Bishop J. M. (1991). The MYC protein activates transcription of the alpha-prothymosin gene. Embo J 10: 133-41. Errede B., Cade R. M., Yashar B. M., Kamada Y., Levin D. E., Irie K., and Matsumoto K. (1995). Dynamics and organization of MAP kinase signal pathways. Mol Reprod Dev 42: 477-85. Fernandes R. S., Gorman A. M., McGahon A., Lawlor M., McCann S., and Cotter T. G. (1996). The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Leukemia 10 Suppl 2: s17-21. Frisch S. M., and Francis H. (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-26. Frisch S. M., Vuori K., Ruoslahti E., and Chan-Hui P. Y. (1996). Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-9. Garcia P., Nieto A., Sanchez M. A., Pizarro M., and Flores J. M. (2004). Expression of alphav, alpha4, alpha5 and beta3 integrin subunits, fibronectin and vitronectin in goat peri-implantation. Anim Reprod Sci 80: 91-100. Giroux S., Tremblay M., Bernard D., Cardin-Girard J. F., Aubry S., Larouche L., Rousseau S., Huot J., Landry J., Jeannotte L., and Charron J. (1999). Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9: 369-72. Guan H., Zu G., Xie Y., Tang H., Johnson M., Xu X., Kevil C., Xiong W. C., Elmets C., Rao Y., Wu J. Y., and Xu H. (2003). Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J Immunol 171: 6519-26. Gustin M. C., Albertyn J., Alexander M., and Davenport K. (1998). MAP kinase pathways in the yeast Saccharomyces cerevisiae. Microbiol Mol Biol Rev 62: 1264-300. Hanahan D., and Weinberg R. A. (2000). The hallmarks of cancer. Cell 100: 57-70. Hanks S. K., Calalb M. B., Harper M. C., and Patel S. K. (1992). Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A 89: 8487-91. Hoffman B., and Liebermann D. A. (1994). Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive & negative modulators. Oncogene 9: 1807-12. Holmes G. P., Negus K., Burridge L., Raman S., Algar E., Yamada T., and Little M. H. (1998). Distinct but overlapping expression patterns of two vertebrate slit homologs implies functional roles in CNS development and organogenesis. Mech Dev 79: 57-72. Honma N., Genda T., Matsuda Y., Yamagiwa S., Takamura M., Ichida T., and Aoyagi Y. (2006). MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 86: 687-96. Howitt J. A., Clout N. J., and Hohenester E. (2004). Binding site for Robo receptors revealed by dissection of the leucine-rich repeat region of Slit. Embo J 23: 4406-12. Hueber A. O., and Evan G. I. (1998). Traps to catch unwary oncogenes. Trends Genet 14: 364-7. Huguet E. L., Smith K., Bicknell R., and Harris A. L. (1995). Regulation of Wnt5a mRNA expression in human mammary epithelial cells by cell shape, confluence, and hepatocyte growth factor. J Biol Chem 270: 12851-6. Huminiecki L., Gorn M., Suchting S., Poulsom R., and Bicknell R. (2002). Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79: 547-52 Hynes R. O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25. Ito K. (2006). Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58: 186-99. Itoh A., Miyabayashi T., Ohno M., and Sakano S. (1998). Cloning and expressions of three mammalian homologues of Drosophila slit suggest possible roles for Slit in the formation and maintenance of the nervous system. Brain Res Mol Brain Res 62: 175-86. Jung E. M., Lim J. H., Lee T. J., Park J. W., Choi K. S., and Kwon T. K. (2005). Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26: 1905-13. Kidd T., Brose K., Mitchell K. J., Fetter R. D., Tessier-Lavigne M., Goodman C. S., and Tear G. (1998). Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell 92: 205-15. Koura A. N., Liu W., Kitadai Y., Singh R. K., Radinsky R., and Ellis L. M. (1996). Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 56: 3891-4. Kraut R., and Zinn K. (2004). Roundabout 2 regulates migration of sensory neurons by signaling in trans. Curr Biol 14: 1319-29. Kumar R., Mandal M., Lipton A., Harvey H., and Thompson C. B. (1996). Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2: 1215-9. Lewis T. S., Shapiro P. S., and Ahn N. G. (1998). Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139. Liu Z., Patel K., Schmidt H., Andrews W., Pini A., and Sundaresan V. (2004). Extracellular Ig domains 1 and 2 of Robo are important for ligand (Slit) binding. Mol Cell Neurosci 26: 232-40. Marillat V., Cases O., Nguyen-Ba-Charvet K. T., Tessier-Lavigne M., Sotelo C., and Chedotal A. (2002). Spatiotemporal expression patterns of slit and robo genes in the rat brain. J Comp Neurol 442: 130-55. McGill G., Shimamura A., Bates R. C., Savage R. E., and Fisher D. E. (1997). Loss of matrix adhesion triggers rapid transformation-selective apoptosis in fibroblasts. J Cell Biol 138: 901-11. McLean G. W., Carragher N. O., Avizienyte E., Evans J., Brunton V. G., and Frame M. C. (2005). The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5: 505-15. Motti M. L., Califano D., Baldassarre G., Celetti A., Merolla F., Forzati F., Napolitano M., Tavernise B., Fusco A., and Viglietto G. (2005). Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 26: 1021-34. Nabeshima K., Inoue T., Shimao Y., and Sameshima T. (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-64. Nguyen-Ba-Charvet K. T., Picard-Riera N., Tessier-Lavigne M., Baron-Van Evercooren A., Sotelo C., and Chedotal A. (2004). Multiple roles for slits in the control of cell migration in the rostral migratory stream. J Neurosci 24: 1497-506. Patel B. N., and Van Vactor D. L. (2002). Axon guidance: the cytoplasmic tail. Curr Opin Cell Biol 14: 221-9. Piper M., Georgas K., Yamada T., and Little M. (2000). Expression of the vertebrate Slit gene family and their putative receptors, the Robo genes, in the developing murine kidney. Mech Dev 94: 213-7. Prasad A., Fernandis A. Z., Rao Y., and Ganju R. K. (2004). Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 279: 9115-24. Ruoslahti E., and Reed J. C. (1994). Anchorage dependence, integrins, and apoptosis. Cell 77: 477-8. Schaller M. D., Borgman C. A., Cobb B. S., Vines R. R., Reynolds A. B., and Parsons J. T. (1992). pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 89: 5192-6. Simpson J. H., Bland K. S., Fetter R. D., and Goodman C. S. (2000). Short-range and long-range guidance by Slit and its Robo receptors: a combinatorial code of Robo receptors controls lateral position. Cell 103: 1019-32. Stein E., and Tessier-Lavigne M. (2001). Hierarchical organization of guidance receptors: silencing of netrin attraction by slit through a Robo/DCC receptor complex. Science 291: 1928-38. Steinman R. A., Wentzel A., Lu Y., Stehle C., and Grandis J. R. (2003). Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene 22: 3608-15. Thompson C. B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-62. Vanhaesebroeck B., Leevers S. J., Panayotou G., and Waterfield M. D. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22: 267-72. Vlahos C. J., Matter W. F., Hui K. Y., and Brown R. F. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-8. Vutskits G. V., Salmon P., Mayor L., Vutskits L., Cudre-Mauroux C., Soriano J., Montesano R., Maillet P., and Sappino A. P. (2006). A role for atm in E-cadherin-mediated contact inhibition in epithelial cells. Breast Cancer Res Treat. Wang C. J., Xue X. B., Yi J. L., Chen K., Zheng J. W., Wang J., Zeng J. P., and Xu R. H. (2006). Melanoma differentiation-associated gene-7, MDA-7/IL-24, selectively induces growth suppression, apoptosis in human hepatocellular carcinoma cell line HepG2 by replication-incompetent adenovirus vector. World J Gastroenterol 12: 1774-9. Wang C. Y., Mayo M. W., and Baldwin A. S., Jr. (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-7. Wang K. H., Brose K., Arnott D., Kidd T., Goodman C. S., Henzel W., and Tessier-Lavigne M. (1999). Biochemical purification of a mammalian slit protein as a positive regulator of sensory axon elongation and branching. Cell 96: 771-84. Wang L., and Adamo M. L. (2000). Cell density influences insulin-like growth factor I gene expression in a cell type-specific manner. Endocrinology 141: 2481-9. Wang T. C., Jee S. H., Tsai T. F., Huang Y. L., Tsai W. L., and Chen R. H. (2005). Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. Br J Dermatol 153: 282-9. Wong K., Park H. T., Wu J. Y., and Rao Y. (2002). Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev 12: 583-91. Wu J. Y., Feng L., Park H. T., Havlioglu N., Wen L., Tang H., Bacon K. B., Jiang Z., Zhang X., and Rao Y. (2001). The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 410: 948-52. Wu W., Wong K., Chen J., Jiang Z., Dupuis S., Wu J. Y., and Rao Y. (1999). Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature 400: 331-6. Xian J., Clark K. J., Fordham R., Pannell R., Rabbitts T. H., and Rabbitts P. H. (2001). Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci U S A 98: 15062-6. Yuan R. H., Jeng Y. M., Chen H. L., Lai P. L., Pan H. W., Hsieh F. J., Lin C. Y., Lee P. H., and Hsu H. C. (2006). Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. Young P. R. (1998). Pharmacological modulation of cytokine action and production through signaling pathways. Cytokine Growth Factor Rev 9: 239-57. Zallen J. A., Yi B. A., and Bargmann C. I. (1998). The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C. elegans. Cell 92: 217-27. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31491 | - |
dc.description.abstract | ROBO1 (Roundabout human homologous-1) 是一位於細胞膜上的接受器,最初發現在果蠅的神經發育過程中,和其配位子 (ligand) SLIT2鍵結後,會產生排拒作用,而使神經細胞不往有SLIT2的方向移動。ROBO1和SLIT2造成的排拒作用,也出現在其他物種,其他種類的細胞和癌細胞中,如:白血球細胞,乳癌細胞。近年來的研究發現,ROBO1在肝細胞癌及直腸癌,有過量的表現。本實驗室利用mRNA分示法,發現ROBO1 variant 2 isoform (ROBO1B) 在肝細胞癌過量表現。
因為發現ROBO1B在肝細胞癌中過量表現,因此我們利用RNAi技術,降低ROBO1B的表現量,來探討ROBO1B在肝細胞癌中扮演的角色 (oncogene or tumor suppressor gene?)。實驗結果發現,ROBO1B表現量降低後。HA22T細胞株在細胞移動實驗及transwell實驗中,細胞移動及侵犯的能力皆下降 (p value分別是:p<0.01, p<0.01),另外HA22T及HuH-7兩株細胞株在3D collagen I gel 實驗中,ROBO1B表現量降低的細胞,生長出比控制組少且短的突起。在細胞生長能力方面,HA22T細胞株ROBO1B表現量降低後,在細胞生長 (MTT assay) 和細胞非貼附性生長 (soft agar assay) 實驗,生長速率都增加 (p<0.05, p<0.001)。但是相反的,ROBO1B表現量降低後,在HuH-7細胞株,細胞生長並不受影響,而細胞非貼附性生長 (soft agar assay) 實驗,生長速率卻是降低 (p<0.005),在以HuH-7建立的穩定細胞株B4, B14, B43中,在細胞非貼附性生長 (soft agar assay) 實驗,和In vivo.的動物實驗,生長速率皆降低 (分別soft agar:p<0.0001, p<0.0001, p<0.005,動物實驗:p<0.01, p=0.02, p=0.17)。在細胞貼附實驗上, HuH-7細胞株對collagen IV及laminin的貼附力降低 (p<0.005, p<0.01),但HA22T細胞株對vitronectin的貼附力卻升高 (p<0.001)。我們尋找這兩株細胞在ROBO1B的表現量降低後,細胞生長和細胞貼附實驗呈現不同表現的原因。 我們檢測細胞內與ROBO1B關係密切的SLIT2之表現量,發現HA22T ROBO1B表現量降低後,SLIT2表現量升高,HuH-7則是無SLIT2的表現。在我們做了臨床病理學的分析後發現,若將ROBO1B和SLIT2的表現量做交叉比對,發現對細胞最好的情況是ROBO1B和SLIT2都高量表現,ROBO1B或SLIT2任一方表現量降低時,腫瘤惡化的程度都明顯升高,因此推論,內生性ROBO1B和SLIT2表現量的平衡,是非常重要的。因此我們推論,在討論ROBO1B對細胞造成的影響的同時,或許不能忽略SLIT2的重要性,探討ROBO1B和SLIT2在細胞中的表現,甚至和其他相關分子之間相互影響,是我們將來的課題。 另外在細胞培養的過程中,意外的發現HA22T及HuH-7兩株肝癌的細胞株,ROBO1B表現量會隨著細胞密度增加而升高。將細胞施予抑制劑後,兩株細胞在有curcumin抑制劑 (AP-1抑制劑—JNK訊息傳遞路徑之轉錄因子) 存在下,ROBO1B表現量皆降低。收取培養第二天及第五天的細胞,測量蛋白表現量,發現細胞在第五天時,ROBO1B和c-jun (AP-1 subunit) 的表現皆升高。已知ROBO1B有兩個AP-1的鍵結位置 (binding site)。因此我們推論,ROBO1B可能被JNK訊息傳遞路徑所調控。 | zh_TW |
dc.description.abstract | ROBO1 (Roundabout human homologous-1), a transmembrane receptor, was first discovered in Drosophila neuron development. Interaction with its ligand - SLIT2, ROBO1 causes a repellent signaling preventing the cell migration toward SLIT2 side. The repulsion effect also occurs in other cell types or tumor cells in different species, such as human leukocytes and breast cancer. Recent studies have shown the overexpression of ROBO1 in human hepatocellular carcinoma (HCC) and colorectal cancer. We also observed that ROBO1 variant 2 (ROBO1B) was often overexpressed HCC. With its frequent overexpression in HCC and its membrane protein nature, we tried to evaluate the potential of ROBO1B as a novel therapeutic target of HCC using the RNAi technique to knockdown ROBO1B. We demonstrated that the ROBO1B knockdown could significantly block the cell migration in wound healing and transwell invasion capability of HA22T (p<0.01, p<0.01). Further, ROBO1B knockdown could dramatically reduced the invasion phenotype of both HA22T and HuH-7 HCC cells in 3-D gel, as manifested by the fewer and shorter cytoplasmic processes. Despite the similarities of the reduced invasive phenotypes, HA22T and HuH-7 cells exhibited significant differences in cell growth ability after RNAi knockdown of ROBO1B in both anchorage-dependent and –independent cell growth. ROBO1B RNAi by transient transfection of RNAi oligos led to dramatic decrease in the colony formation ability in soft agar assay, p<0.005, in HuH-7 cell line. Further, we also established three stable lines of ROBO1B knowndown HuH-7 cells (named B4, B14, B43), which also showed significant decrease in anchorage-independent growth, p<0.0001, p<0.0001, and p<0.005, respectively. These three stable knockdown clones also exhibited reduction in tumor growth in SCID mice, p<0.01, p=0.02, and p=0.17, respectively. In contrast to our expectation, ROBO1B knockdown caused increased in cell growth of HA22T cells in both MTT and soft agar assay (p<0.05 and p<0.001, respectively). We then did cell adhesion assay. ROBO1B knockdown HuH-7 cells had decreased adhesion ability to collagen IV and laminin (p<0.005, p<0.01), whereas ROBO1B knockdown HA22T cells showed increase in adhesion ability to vitronectin (p<0.001). Besides, we found that SLIT2 mRNA level remained undetectable in HuH-7 cells, whereas the SLIT2 levels increased in HA22T cells after ROBO1B knockdown. These contradictory findings, together with the close relation between ROBO1B and SLIT2 in axonal guidance, and the opposite expression, ROBO1B overexpression and SLIT2 downregulation in HCC, prompted us to review the role of ROBO1B and SLIT2 in human HCC. We found that HCC with expression of both ROBO1B and SLIT2 had lower frequency of vascular invasion as compared with HCC with ROBO1B overexpression but SLIT2 downregulation, p=0.028, suggesting that SLIT2 is an endogenous inhibitor of ROBO1B-mediated tumor invasion. More studies are warranted to elucidate the complex interacting roles of ROBO1B and its ligands in HCC and very likely other types of human cancer.
In the study of cell growth, it came to our surprise that the mRNA levels of ROBO1B of both HA22T and HuH-7 cells were increased as the cell density increased. Using specific inhibitors, both cell lines exhibited dramatic morphologic changes, manifested by cell round-up, and had dramatically decreased ROBO1B mRNA level after curcumin (AP-1 inhibitor - the transcription factor of JNK pathway) treatment. These findings suggest that ROBO1B is regulated by the AP-1 pathway, and deserves to be further elucidated. Consistent with this suggestion, ROBO1B has two AP-1 sites in the promoter region. Besides, ROBO1B and c-jun protein levels of HA22T and HuH-7 cells increased in parallel at high cell density (day 5 culture) as compared with culture at low cell density (day 2). These findings suggest that ROBO1B is regulated by JNK pathway. We also showed that ROBO1B in HA22T was decreased after LY294002 (PI3K inhibitor), suggesting that PI3K might be also involved in the activation of ROBO1B transcription. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:13:44Z (GMT). No. of bitstreams: 1 ntu-95-R92444007-1.pdf: 2756933 bytes, checksum: aaf5ef437652a77277344529f6d0b016 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 摘要 i
Abstract iii 目錄 v 圖目錄 vii 表目錄 ix 導論 1 1 肝癌類型 1 2 肝細胞癌的發生率及死亡率 2 3 肝細胞癌的危險因子 2 4 病原致癌機制之論述 3 5 肝細胞癌的診斷方式 4 6 肝細胞癌的治療及預後 4 7 腫瘤標誌 5 8 肝細胞癌特異性表現基因篩選 6 9 肝癌特異性表現基因-Roundabout human homologous-1(Robo1)….... 6 9.1 Robo1 的發現 6 9.2 Robo及Slit的構造及作用 7 9.3 Robo-Slit的其他作用(function) 8 9.4 Robo和Slit作用引發的訊息傳遞 9 9.5 Robo-Slit與癌症的關係 12 9.6 基因分示法 13 材料與方法 15 1 材料 15 1.1 肝癌檢體 15 1.2 組織分類 15 1.3 試劑 (Reagent) 15 1.4 溶液備製 16 2 方法 16 2.1 組織之核糖核酸萃取 (Total RNA extraction from tissues) 16 2.2 反轉錄-聚合酶鏈鎖反應(RT-PCR) 17 2.3 西方墨點法 (western blot) 18 2.4 細胞傷口癒合實驗 (Wound healing assay) 19 2.5 3-D collagen assay 19 2.6 Transwell assay 20 2.7 免疫螢光染色 (Immunofluorescence Stains) 20 2.8 MTT assay 20 2.9 半固體瓊脂培養基實驗 (Soft agar assay) 21 2.10 動物實驗 (Xenograft tumor in SCID mice) 21 2.11 細胞貼附實驗 (adhesion assay) 21 2.12 抑制劑的處理 (inhibitor treatment) 22 2.13 統計方法 22 結果 23 1 ROBO1B mRNA及蛋白質在肝細胞癌 (HCC) 細胞株的表現 23 2 ROBO1B mRNA表現量隨著細胞密度增加而增多 23 3 抑制劑的影響 23 4 AP-1在細胞中的表現量 23 5 RNAi降低ROBO1B 表現量 24 6 ROBO1B 的調降,降低細胞移動 (migration) 之能力 24 7 ROBO1B 的調降,降低了細胞在collagen type I gel及matrigel中的侵襲 (invasion) 能力 24 8 ROBO1B 的調降,改變細胞內F-actin的分佈 25 9 ROBO1B 調降後,侵襲能力相關蛋白的表現 25 10 ROBO1B 調降與細胞生長的關聯 25 11 ROBO1B RNAi調降的穩定細胞株 (stable line) 的建立 26 12 ROBO1B RNAi調降的穩定細胞株,cell anchorage-independent growth能力降低 26 13 ROBO1B RNAi調降的穩定細胞株,in vivo生長能力降低 26 14 ROBO1B 調降後,細胞生長能力相關蛋白的表現 27 15 ROBO1B 調降後,對細胞貼附能力的影響 27 16 ROBO1B和SLIT2在細胞中的表現 27 17 分析ROBO1B及SLIT2基因與臨床病理學因子的關聯性 27 討論 29 1 ROBO1B的調控:高細胞密度下ROBO1B基因調昇的啟示 29 2 ROBO1B與侵襲能力的關聯 31 3 ROBO1B與細胞生長能力的關聯 32 4 ROBO1B與細胞貼附能力的關聯 33 5 肝細胞癌ROBO1B 與 SLIT2表現的互動關係 34 參考資料 36 圖示及圖表 43 圖 目 錄 圖1 ROBO1 在細胞株的表現量 43 圖2 ROBO1B mRNA表現量隨細胞密度增多而增高 44 圖3A 四種抑制劑PD98059 (MEK1 inhibitor)、LY294002 (PI3K inhibitor)、SB203580 (P38 MAPK inhibitor)、Curcumin (AP-1 inhibitor)的效應 45 圖3B 四種抑制劑PD98059 (MEK1 inhibitor)、LY294002 (PI3K inhibitor)、SB203580 (P38 MAPK inhibitor)、Curcumin (AP-1 inhibitor)的效應 46 圖4 ROBO1B 與AP-1徑路蛋白c-jun表現與細胞密度的關係 47 圖5A 測量ROBO1B RNAi 短暫轉染的效力 48 圖6 Wound healing assay 49 圖7 3D collagen I assay 50 圖8 Transwell assay 51 圖9A ROBO1的調降與F-actin分布的改變 52 圖9B ROBO1的調降與F-actin分布的改變 53 圖10 細胞侵襲能力相關蛋白的表現量 54 圖11 MTT assay 55 圖12A Soft agar assay 56 圖12B Soft agar assay 57 圖13 Soft agar assay 58 圖14 In vivo. Assay 59 圖15 In vivo. Assay 60 圖16 細胞生長能力相關蛋白的表現量 61 圖17A Adhesion assay 62 圖17B Adhesion assay 63 圖18 細胞株短暫轉染ROBO1B RNAi後,SLIT2 mRNA的表現量 64 圖19 HCC內SLIT2 mRNA的表現量 65 表 目 錄 表一 臨床病理學分析肝細胞癌之ROBO1B及SLIT2 mRNA個別的表現和各項病理診斷因子的相關性 66 表二 臨床病理學分析肝細胞癌之ROBO1B及SLIT2 mRNA的合併表現和各項病理診斷因子的相關性 67 表三 細胞經ROBO1B RNAi 調降後,各項實驗數據的綜合整理 68 | |
dc.language.iso | zh-TW | |
dc.title | 肝細胞癌中Robo1訊息傳導功能之研究 | zh_TW |
dc.title | Functional Study of Robol Pathway in Hepatocellular carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李玉梅,呂勝春,許金玉 | |
dc.subject.keyword | 肝細胞癌, | zh_TW |
dc.subject.keyword | Robo1,hepatocellular carcinoma, | en |
dc.relation.page | 68 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-08-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 2.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。